Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Coverage-With-Evidence-Development Guidance In The Works Following MedCAC Meeting

This article was originally published in The Gray Sheet

Executive Summary

The Medicare Evidence Development & Coverage Advisory Committee was charged May 16 with helping CMS better define the evidence threshold under which the agency should or should not pursue a coverage- with-evidence-development policy.


Related Content

Device Makers Seek Clarity On CMS' Plans For Coverage With Evidence Development
Washington Roundup, January 2013
Washington Roundup, November-December 2012
CMS Redefines Coverage-With-Evidence-Development In Draft Guidance
Post-Election Picture: Near-Term Next Steps To Come
Device Makers Want Say In Medicare 'Coverage-With-Evidence-Development' Policy
CMS Coverage-With-Evidence-Development Policy Could Face Revamp
Former Medicare Officials Urge Reforms To Coverage Process
Oncologists Seek To End Restrictions On PET For Staging Cervical Cancer
CMS Offers Two Paths To “Coverage With Evidence” In Revised Guidance





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts